References
[1] VENTOLA C L.Cancer immunotherapy, part 1: current strategies and agents[J].Pharmacy and therapeutics, 2017, 42(6):375-383.
[2] BERRAONDO P, SANMAMED M F, OCHOA M C, et al.Cytokines in clinical cancer immunotherapy[J].British journal of cancer, 2019, 120(1):6-15.
[3] MASSAGUE J.TGF beta in cancer[J].Cell, 2008, 134(2):215-230.
[4] AKHURST R J, HATA A.Targeting the TGF beta signalling pathway in disease[J].Nature reviews drug discovery, 2012, 11(10):790-811.
[5] TAURIELLO D V F, PALOMO-PONCE S, STORK D, et al.TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis[J].Nature, 2018, 554(7693):538-543.
[6] BUTLER J E, MOORE M B, PRESNELL S R, et al.Proteasome regulation of ULBP1 transcription[J].Journal of immunology, 2009,182(10):6600-6609.
[7] CORRALES L, WOO S R, WILLIAMS J B, et al.Antagonism of the STING pathway via activation of the AIM2 inflammasome by intracellular DNA[J].Journal of immunology,2016, 196(7):3191-3198.
[8] SANCHEZ A A, BIVONA A E, CERNY N, et al.Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection[J].NPJ vccines, 2017, 2:9.
[9] HENNESSY E J, PARKER A E, O'NEILL L A.Targeting Toll-like receptors: emerging therapeutics?[J] Nature reviews drug discovery, 2010, 9(4):293-307.
[10] SMITH A J, LI Y, BAZIN H G, et al.Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants[J].Vaccine, 2016, 34(36):4304-4312.
[11] NISHIDA S, TSUBOI A, TANEMURA A, et al.Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: a phase 1 study of safety and immunogenicity assessments[J].Medicine (Baltimore), 2019, 98(33): e16771.(https://www.daowen.com)
[12] SEYA T, TAKEDA Y, TAKASHIMA K, et al.Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy[C]//Proceedings of the Japan Academy, 2018, 94(3):153-160.
[13] GAMAZO C, D’AMELIO C, GASTAMINZA G, et al.Adjuvants for allergy immunotherapeutics[J].Human vaccines & immunotherapeutics, 2017, 13(10):2416-2427.
[14] UDAGAWA M, KUDO-SAITO C, HASEGAWA G, et al.Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation[J].Clinical cancer research, 2006, 12(24):7465-7475.
[15] KAWAI T, AKIRA S.The roles of TLRs, RLRs and NLRs in pathogen recognition[J].International immunology, 2009, 21(4):317-337.
[16] MARTINON F, TSCHOPP J.Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases[J].Cell, 2004, 117(5):561-574.
[17] MATSUMOTO M, TATEMATSU M, NISHIKAWA F, et al.Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo[J].Nature communications, 2015, 6:6280.
[18] SUGIMOTO H, ODA S, OTSUKI T, et al.Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O-2 incorporation by a heme-containing dioxygenase[C]//Proceedings of National Academy of Sciences of the United States of America, 2006,103(8):2611-2616.19.
[19] ZAMANAKOU M, GERMENIS A E, KARANIKAS V.Tumor immune escape mediated by indoleamine 2,3-dioxygenase[J].Immunollgy letters, 2007, 111(2):69-75.
[20] RÖHRIG U F, MAJJIGAPU S R, VOGEL P, et al.Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors[J].Journal of medical chemistry, 2015,58(24):9421-9437.
[21] VACCHELLI E, ARANDA F, EGGERMONT A, et al.Trial watch: IDO inhibitors in cancer therapy[J].Oncoimmunology, 2014, 3(10): e957994.
[22] ZHU H F, LI Y.Small-Molecule targets in tumor immunotherapy[J].Natural products and bioprospecting, 2018, 8(4):297-301.